help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inoue, M.
Right arrow Articles by Teitelbaum, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoue, M.
Right arrow Articles by Teitelbaum, S. L.
Endocrinology Vol. 141, No. 1 284-290
Copyright © 2000 by The Endocrine Society


ARTICLES

Tumor Necrosis Factor {alpha} Regulates {alpha}vß5 Integrin Expression by Osteoclast Precursors in Vitro and in Vivo1

Masaru Inoue, F. Patrick Ross, Jeanne M. Erdmann, Yousef Abu-Amer, Shi Wei and Steven L. Teitelbaum

Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110

Address all correspondence and requests for reprints to: Steven L. Teitelbaum, M.D., Department of Pathology, Washington University School of Medicine, Barnes-Jewish Hospital North, 216 South Kingshighway, St. Louis, Missouri 63110. E-mail: teitelbs{at}medicine.wustl.edu

Early osteoclast precursors, in the form of murine bone marrow macrophages (BMMs), while expressing no detectable {alpha}vß3 integrin, contain abundant {alpha}vß5 and attach to matrix in an {alpha}v integrin-dependent manner. Furthermore, {alpha}vß5 expression by osteoclast precursors progressively falls as they assume the resorptive phenotype. We find the osteoclastogenic agent, tumor necrosis factor-{alpha}, (TNF) down-regulates {alpha}vß5 expression by BMMS via attenuation of ß5 messenger RNA (mRNA) t1/2. Using BMMs from TNF receptor knockout mice we establish the p55 receptor transmits the ß5 suppressive effect. The functional implications of TNF-mediated {alpha}vß5 down-regulation are underscored by the capacity of an {alpha}v inhibitory peptide mimetic to prevent spreading by BMMs expressing abundant {alpha}vß5 while failing to impact those in which the integrin has been diminished by TNF. Finally, ß5 mRNA in BMMs of wild-type mice administered lipopolysaccharide (LPS) progressively falls with time of in vivo treatment. Alternatively, ß5 mRNA does not decline in BMMs of LPS-treated mice lacking both TNF receptors, documenting down-regulation of the ß5 integrin subunit, in vivo, is mediated by TNF. Thus, matrix attachment of osteoclast precursors and mature osteoclasts are governed by distinct {alpha}v integrins which are differentially regulated by specific cytokines.




This article has been cited by other articles:


Home page
EndocrinologyHome page
J. C. Crockett, N. Schutze, D. Tosh, S. Jatzke, A. Duthie, F. Jakob, and M. J. Rogers
The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of {alpha}v{beta}3 and {alpha}v{beta}5
Endocrinology, December 1, 2007; 148(12): 5761 - 5768.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-L. Lin, W. J. S. de Villiers, B. Garvy, S. R. Post, T. R. Nagy, F. F. Safadi, M. C. Faugere, G. Wang, H. H. Malluche, and J. P. Williams
The Effect of Class A Scavenger Receptor Deficiency in Bone
J. Biol. Chem., February 16, 2007; 282(7): 4653 - 4660.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Shi, C. Nathan, D. Schnappinger, J. Drenkow, M. Fuortes, E. Block, A. Ding, T. R. Gingeras, G. Schoolnik, S. Akira, et al.
MyD88 Primes Macrophages for Full-Scale Activation by Interferon-{gamma} yet Mediates Few Responses to Mycobacterium tuberculosis
J. Exp. Med., October 6, 2003; 198(7): 987 - 997.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
R L Wilder
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
Ann Rheum Dis, November 1, 2002; 61(90002): ii96 - 99.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society